AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Researchers at the Duke Human Vaccine Institute successfully created an HIV vaccine candidate that guides key immune cells along an evolutionary pathway to become broadly neutralizing antibodies.

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Newly developed vaccine could protect against emerging SARS-CoV-2 variants and related coronaviruses that may jump from ...

1 月 24 日，赛诺菲宣布其 CD38 单抗「艾沙妥昔单抗」新适应症在国内获批上市，用于与硼替佐米、来那度胺和地塞米松 (VRd)联合，治疗不适合自体干细胞移植 (ASCT)的新诊断的多发性骨髓瘤 (NDMM)成人患者。

To that end, AbbVie bought neuroscience drug developer Cerevel Therapeutics, cancer drug developer ImmunoGen and Alzheimer's therapy developer Aliada in 2024 through deals worth over $20 billion ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.